Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Corporate Update (June 2017)

6 slides from Lumos Pharma's corporate update, Jun 8, 2017

  1. Slide 1: NewLink Genetics Corporation June 8, 2017 Conference Call on GDC-0919 Program

    NewLink Genetics Corporation Nasdaq: NLNK June 8, 2017 Conference Call on GDC-0919 Program

  2. Slide 2: Forward-Looking Disclaimer

    Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that involve substantial risks and uncert

  3. Slide 3: NewLink Participants and Agenda

    Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. NewLink Participants and Agenda 3 Introduction  Jack Henneman, Executive Vice President & CFO GDC-0919 Decision Review  Charles J.

  4. Slide 4: Indoximod plus Pembrolizumab (PD-1): Best Response by RECIST Criteria

    Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Indoximod plus Pembrolizumab (PD-1) 4 Best Response by RECIST Criteria n (%) n = 51 † Overall Response Rate 30 (59) Complete Response

  5. Slide 5: Indoximod plus Pembrolizumab (PD-1): Clinical Benefit and Disease Control Rate

    Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Indoximod plus Pembrolizumab (PD-1) 5 Impressive Clinical Benefit and Disease Control Rate *SD of primary lesion; new non-target lesi

  6. Slide 6: Indoximod plus Provenge (sipuleucel-T) Vaccine

    Zakharia Y, et al. Oral presentation at: 107th Annual Meeting of the American Association for Cancer Research (AACR); April 1-5, 2017; Washington, DC. Abstract CT117. Indoximod plus Provenge (sipuleucel-T) Vaccine 6 Randomized, Double Blind, Placebo Controlled Phase 2 Study Abstract 3066 Jha et al.

NewLink Genetics — Corporate Update (June 2017) on 6ix